Trial | Follow-up (months) | Comparison | Patients analyzed | ARR experimental arm | ARR control arm | Relapse rate ratio | EDSS progression experimental arm | EDSS Progression control arm | Disability risk ratio |
---|---|---|---|---|---|---|---|---|---|
Comi G, et al., [17] | 24 | IFNB-1a 22 μg vs. Placebo | 309 | 0.33 | 0.43 | 0.767 | 15.00 | 20.00 | 0.750 |
Hartung HP, et al. [24] | 36 | Mitoxantrone 12Â mg vs. Placebo | 124 | 0.35 | 1.02 | 0.343 | 8.00 | 22.00 | 0.364 |
Durelli L, et al. [18] | 24 | IFNB-1a 30 μg vs. IFNB-1b 250 μg | 188 | 0.50 | 0.70 | 0.714 | 13.00 | 30.00 | 0.433 |
Rudick RA, et al. [38] | 24 | IFNB-1a plus Natalizumab vs. IFNB- 1a | 1,171 | 0.34 | 0.75 | 0.453 | 23.00 | 29.00 | 0.793 |
Havrdova E, et al. [25] | 24 | IFNB-1a plus azathioprinethioprine vs. IFNB-1a | 116 | 0.91 | 1.05 | 0.867 | 20.70 | 16.80 | 1.232 |
Havrdova E, et al. [25] | 24 | IFNB-1a plus azathioprine plus prednisone vs. IFNB-1a | 120 | 0.73 | 1.05 | 0.695 | 17.50 | 16.80 | 1.042 |
Mikol DD, et al. [32] | 22 | IFNB-1a vs. Glatiramer acetate | 764 | 0.29 | 0.30 | 0.967 | 8.70 | 11.70 | 0.744 |
Ravnborg M, et al. [37] | 36 | IFNB-1a plus Methylprednisolone vs. IFNB-1a | 338 | 0.21 | 0.33 | 0.636 | 25.00 | 28.50 | 0.877 |
Sorensen P, et al. [39] | 22 | IFNB-1a plus Methylprednisolone vs. IFNB-1a | 130 | 0.22 | 0.59 | 0.373 | 16.00 | 25.00 | 0.640 |
O’Connor P, et al. [34] | 42 | Glatiramer acetate vs. IFNB-1b 250 μg | 1,158 | 0.34 | 0.36 | 0.944 | 20.50 | 22.30 | 0.919 |
O’Connor P, et al. [34] | 42 | Glatiramer acetate vs. IFNB-1b 500 μg | 1,100 | 0.34 | 0.33 | 1.030 | 20.50 | 22.30 | 0.919 |
Gonsette RE, et al. [23] | 24 | IFNB-1b plus Inosine vs. IFNB-1b | 157 | 0.50 | 0.38 | 1.316 | 17.78 | 18.18 | 0.978 |
Coles AJ, et al. [16] | 36 | Alemtuzumab vs. IFNB-1a | 333 | 0.1 | 0.36 | 0.278 | 9.00 | 26.20 | 0.344 |
Kappos L, et al. [30] | 24 | Fingolimod 0.5Â mg vs. Placebo | 843 | 0.18 | 0.40 | 0.450 | 17.70 | 24.10 | 0.734 |
Kappos L, et al. [30] | 24 | Fingolimod 1.25Â mg vs. Placebo | 847 | 0.16 | 0.40 | 0.400 | 16.60 | 24.10 | 0.689 |
Polman CH, et al. [36] | 24 | Natalizumab vs. Placebo | 942 | 0.23 | 0.73 | 0.315 | 17.00 | 29.00 | 0.586 |
Clanet M, et al. [14] | 36 | IFNB-1a 30 μg vs. IFNB-1a 60 μg | 802 | 0.81 | 0.77 | 1.052 | 37.00 | 37.00 | 1.000 |
Ebers GC, et al. [9] | 104 | IFNB-1a 22 μg vs. Placebo | 376 | 0.91 | 1.28 | 0.711 | 30.00 | 38.00 | 0.789 |
Ebers GC, et al. [9] | 104 | IFNB-1a 44 μg vs. Placebo | 373 | 0.87 | 1.28 | 0.676 | 26.50 | 38.00 | 0.697 |
Johnson KP, et al. [27] | 24 | Glatiramer acetate vs. Placebo | 251 | 0.59 | 0.84 | 0.702 | 21.60 | 24.60 | 0.878 |
Achiron A, et al. [11] | 24 | Immunoglobulin vs. Placebo | 40 | 0.59 | 1.61 | 0.366 | 13.70 | 17.10 | 0.801 |
Baumhackl U, et al. [13] | 24 | Hydrolytic enzymes vs. Placebo | 291 | 0.63 | 0.74 | 0.851 | 28.00 | 26.00 | 1.077 |
Fazekas F, et al. [20] | 24 | Immunoglobulin vs. Placebo | 148 | 0.52 | 1.26 | 0.413 | 17.00 | 23.00 | 0.739 |
Millefiorini E, et al.[33] | 24 | Mitoxantrone vs. Placebo | 51 | 0.445 | 1.31 | 0.340 | 7.00 | 37.00 | 0.189 |
Jacobs LD, et al. [26] | 24 | IFNB-1a vs. Placebo | 172 | 0.61 | 0.90 | 0.678 | 21.10 | 33.30 | 0.633 |
Ebers GC, et al. [8] | 36 | IFNB-1b 1.6 MIU vs. Placebo | 228 | 1.05 | 1.21 | 0.868 | 28.00 | 28.00 | 1.000 |
Ebers GC, et al. [8] | 36 | IFNB-1b 8 MIU vs. Placebo | 227 | 0.84 | 1.21 | 0.694 | 20.00 | 28.00 | 0.714 |
van de Wyngaert FA, et al. [40] | 36 | Mitoxantrone vs. Methylprednisolone | 28 | 0.26 | 1.00 | 0.260 | 21.00 | 21.00 | 1.000 |
Andersen O et al. [12] | 36 | IFNB-1a 22 μg vs. Placebo | 364 | 0.25 | 0.27 | 0.926 | 41.00 | 38.00 | 1.079 |
Cohen JA, et al. [15] | 24 | IFNB-1a 60 μg vs. Placebo | 379 | 0.20 | 0.30 | 0.667 | 28.50 | 33.70 | 0.846 |
Panitch H, et al. [35] | 36 | IFNB-1b 160 μg vs. Placebo | 622 | 0.20 | 0.28 | 0.714 | 39.00 | 34.00 | 1.147 |
Panitch H, et al. [35] | 36 | IFNB-1b 250 μg vs. Placebo | 625 | 0.16 | 0.28 | 0.571 | 32.00 | 34.00 | 0.941 |
Kappos L, et al. [28] | 36 | IFNB-1b vs. Placebo | 718 | 0.44 | 0.64 | 0.688 | 38.90 | 49.70 | 0.783 |
Edan G, et al. [41] | 36 | Mitoxantrone 12 mg/m2 vs. IFNβ-1b 250 μg | 109 | 0.39 | 0.71 | 0.549 | 9.10 | 25.90 | 0.351 |
Freedman MS, et al. [42] | 24 | MBP8298 vs. Placebo in DR2+ and/or DR4+ haplotypes | 513 | 0.13 | 0.14 | 0.929 | 30.70 | 27.80 | 1.104 |
Freedman MS, et al. [42] | 24 | MBP8298 vs. Placebo in DR2- and/or DR4- haplotypes | 99 | 0.08 | 0.20 | 0.400 | 28.30 | 35.80 | 0.791 |
Comi G, et al. [45] | 24 | Laquinimod 0.6Â mg vs. Placebo | 1,106 | 0.30 | 0.39 | 0.769 | 11.10 | 15.70 | 0.707 |
Cohen JA, et al. [43] | 24 | Alemtuzumab 12 mg vs. IFNβ-1a 44 μg | 563 | 0.18 | 0.39 | 0.462 | 8.00 | 11.12 | 0.719 |
Coles AJ, et al. [44] | 24 | Alemtuzumab 12 mg vs. IFNβ-1a 44 μg | 667 | 0.26 | 0.52 | 0.500 | 12.71 | 21.13 | 0.602 |
Fox RJ, et al. [46] | 24 | Dimethyl fumarate 240Â mg BID vs. Placebo | 480 | 0.22 | 0.40 | 0.550 | 13.00 | 17.00 | 0.765 |
Fox RJ, et al. [46] | 24 | Dimethyl fumarate 240Â mg TID vs. Placebo | 466 | 0.20 | 0.40 | 0.500 | 13.00 | 17.00 | 0.765 |
Fox RJ, et al. [46] | 24 | Glatiramer acetate vs. Placebo | 471 | 0.29 | 0.40 | 0.725 | 16.00 | 17.00 | 0.941 |